ACO and Payer Leadership Insights: Recognizing the Value of Personalized Medicine in Oncology
With so many payment and care organization approaches, ACOs are focused on reshaping accountability by shifting the risk from payers to providers. Ultimately, this move should result in reduced costs and a better experience of care and health across a population, but what impact will personalized medicine have on ACOs and payers?
In the era of accelerating scientific and medical advancements in personalized oncology, it is increasingly important to explore the impact on payers as medical advances and innovative groundbreaking concepts are adopted.
During this 60-minute fireside chat, Dr. Richard Schilsky, former Executive Vice President and Chief Medical Officer of ASCO and Dr. Lee Newcomer, former Chief Medical Officer of UnitedHealth Group, will:
· Discuss pioneering medical technologies that can improve patient outcomes AND improve the value of therapies that payers pay for
· Address the challenges and opportunities to obtain robust, consistent, and rigorous outcomes using data from clinical trials and real- world sources
· Describe the real and potential impact on national guidelines of emerging personalized oncology technologies and strategies
· Consider how the needs of patients and ACOs can be met through use of personalized medicine approaches to cancer care
Speakers:
Dr. Richard Schilsky, former EVP & CMO, ASCO
Dr. Lee Newcomer, former CMO, UnitedHealth Group
